STOCK TITAN

Iovance interim CEO exercises options for 200,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

At Iovance Biotherapeutics, Inc., director and Interim CEO & General Counsel Frederick G. Vogt exercised a fully vested stock option on November 11, 2026, covering 200,000 common shares at an exercise price of $7.55 per share. The option was scheduled to expire November 14, 2026. The issuer withheld 186,651 shares for the exercise price and 4,652 for mandatory tax withholding; no shares were sold in the open market. The exercise increased Vogt's holdings by 8,697 shares and produced no cash proceeds.

Insider Vogt Frederick G
Role Interim CEO & General Counsel
Type Security Shares Price Value
Exercise Stock Option (right to buy) F4 200,000 $0.00 $0.00
Exercise Common Stock F1 200,000 $7.55 $1.51M
Exercise Price or Tax Liability Common Stock F2, F3 191,303 $8.09 $1.55M
Holdings After Transaction: Stock Option (right to buy) — 0 options (Direct); Common Stock — 604,144 shares (Direct)
Holdings Before and After: Stock Option (right to buy), 200,000 to 0 options (Direct); Common Stock, 595,447 to 604,144 shares (Direct)
Footnotes (4)
  1. F1. Represents shares acquired upon the exercise of a stock option granted on November 14, 2016 covering 200,000 shares of the Issuer's common stock at an exercise price of $7.55 per share. The option was scheduled to expire on November 14, 2026. The Reporting Person exercised the option because of its impending expiration, during an open trading window, and did not receive any cash proceeds from the exercise. The net result of the exercise was an increase of 8,697 shares in the Reporting Person's holdings of the Issuer's common stock.
  2. F2. Represents shares withheld by the Issuer in a net exercise of the option, consisting of 186,651 shares withheld to pay the exercise price of the option and 4,652 shares withheld to satisfy the mandatory tax withholding requirements upon exercise of the option, in each case valued at the closing price of the Issuer's common stock on the transaction date. No shares were sold in the open market. This is not an open market sale of securities.
  3. F3. Represents common stock remaining after deducting the common stock withheld for the exercise price and taxes.
  4. F4. The option was fully vested and exercisable as of the transaction date.
Shares covered by option exercise 200,000 shares Exercised on November 11, 2026
Exercise price $7.55 per share Price per share for the stock option exercise
Shares withheld for exercise price 186,651 shares Withheld by the issuer in the net exercise
Shares withheld for tax 4,652 shares Withheld for mandatory tax requirements upon exercise
Increase in Vogt's holdings 8,697 shares Net increase from the option exercise
Closing price used to value withheld shares $8.09 per share Withheld shares were valued at the closing price on November 11, 2026
net exercise financial
"in a net exercise of the option"
A net exercise is a way to convert stock options into shares without paying cash up front: instead of handing over money to buy the optioned shares, the holder receives only the number of shares equal to the option’s value after the company withholds a portion of shares to cover the exercise price and taxes. It matters to investors because it changes how many new shares are issued, affects dilution of existing shareholders, and alters company cash flow compared with a cash exercise.
fully vested financial
"The option was fully vested and exercisable as of the transaction date."
open trading window technical
"during an open trading window"
A designated period when company executives, directors and certain employees are permitted to buy or sell their employer’s stock under the company’s trading policy because material information has been disclosed. Think of it like scheduled store hours after a big delivery: it reduces the risk of trading on secret information, and investors watch insider activity during these windows as a signal of how those closest to the business view its prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IOVA shares did Frederick G. Vogt receive from the option exercise?

Frederick G. Vogt acquired 200,000 Iovance common shares by exercising options at an exercise price of $7.55 per share on November 11, 2026.

Why did IOVA's interim CEO exercise the stock option?

Frederick G. Vogt exercised the fully vested option because it was approaching its November 14, 2026 expiration; the exercise occurred during an open trading window.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vogt Frederick G

(Last)(First)(Middle)
C/O IOVANCE BIOTHERAPEUTICS, INC.
300 ROUSE BLVD.

(Street)
PHILADELPHIA PENNSYLVANIA 19112

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Interim CEO & General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)11/11/2026M200,000A$7.55795,447D
Common Stock(2)11/11/2026F191,303D$8.09604,144(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$7.5511/11/2026M200,000 (4)11/14/2026Common stock200,000$00D
Explanation of Responses:
1. Represents shares acquired upon the exercise of a stock option granted on November 14, 2016 covering 200,000 shares of the Issuer's common stock at an exercise price of $7.55 per share. The option was scheduled to expire on November 14, 2026. The Reporting Person exercised the option because of its impending expiration, during an open trading window, and did not receive any cash proceeds from the exercise. The net result of the exercise was an increase of 8,697 shares in the Reporting Person's holdings of the Issuer's common stock.
2. Represents shares withheld by the Issuer in a net exercise of the option, consisting of 186,651 shares withheld to pay the exercise price of the option and 4,652 shares withheld to satisfy the mandatory tax withholding requirements upon exercise of the option, in each case valued at the closing price of the Issuer's common stock on the transaction date. No shares were sold in the open market. This is not an open market sale of securities.
3. Represents common stock remaining after deducting the common stock withheld for the exercise price and taxes.
4. The option was fully vested and exercisable as of the transaction date.
/s/ Frederick G. Vogt11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading